The CONTEXT trial: Real world clinical use of GIQuant—a motility MRI based activity biomarker for small bowel Crohn’s disease

Alex Menys

doi:10.1093/ecco-jcc/jjag037

The CONTEXT trial: Real world clinical use of GIQuant—a motility MRI based activity biomarker for small bowel Crohn’s disease

2026-06-10

0

OA

AI

A

Alex Menys *

I

Iyad Naim

J

Joy Barber

K

Kamal Patel

N

Nirav Patel

A

Attah Ocholi

S

Samantha Baillie

N

Nkem Onyeador

V

Victoria Jennings

S

Sudheer Vuyyuru

C

Christopher Clarke

R

Rahul Munyal

G

Gauraang Bhatnagar

T

Thomas Shepherd

L

Laurence Bourn

S

Sara Upponi

J

Juan De la Revilla Negro

A

Anish Kuzhiyanjal

J

Jimmi Limdi

A

Aung Win

P

Priyanka Ghodekar

A

Afaq Siddiqui

D

Damian Tolan

H

Heather Fitzke

W

William Weston

P

Paul Harrow

J

Jie Han Yeo

M

M Hameed

S

Stuart A Taylor

G

Gordon William Moran

DOI：10.1093/ecco-jcc/jjag037

Original

Original request for help

Save

Abstract

En 中文

Motility MRI is a validated marker of small bowel Crohn’s disease (CD) activity. Objective assessment of small bowel motility with GIQuant (Motilent, London, U.K.) may have a valuable role to play in personalised patient care. The aim of this study was to assess the impact of implementing GIQuant on clinical impressions around treatment response in small bowel CD.

The CONTEXT trial: Real world clinical use of GIQuant—a motility MRI based activity biomarker for small bowel Crohn’s disease

Abstract

Journal

Organization